Formulation development and evaluation of transdermal patch of piroxicam for treating dysmenorrhoea

Nilesh M. Mahajan; Grishma H. Zode; Debarshi Kar Mahapatra; Sonali Thakre; Nitin Dumore; Purushottam S. Gangane

doi:10.7324/JAPS.2018.81105

Abstract References Article Metrics Similar Articles Request Permission Related Search Citation Alert By Google Scholar Comment On This Article

Abstract

Dysmenorrhea (pain with menstruation) affects up to 90% of adolescent and young women. Despite the availability of a variety of effective pharmacological treatments, it is frequently left untreated. Non-steroidal anti-inflammatory drugs (NSAIDs) are the best-established initial therapy for dysmenorrhoea. When NSAIDs are given through the oral route, it causes several side-effects like gastric disturbance, stomach ulcer, nausea, vomiting, etc. Piroxicam is an NSAID utilized for treating dysmenorrhoea in the form of tablet formulation. As mentioned above, it also suffers from similar adverse effects. To overcome those conditions, the transdermal patch of piroxicam can serve as a better alternative to the tablets which serves as the safe alternative over oral route. In the present research, the transdermal patch of piroxicam was fabricated by using sustained release hydrophilic and lipophilic polymers containing permeation enhancer and thoroughly evaluated. The transdermal patches of piroxicam were prepared using the combination of polymers, hydroxypropyl methylcellulose E15, polyvinylpyrrolidone (PVP) K30, and ethyl cellulose in different concentration with sodium lauryl sulfate as the permeation enhancer and polyethylene glycol 400 as the plasticizer was used for the formulation of transdermal drug delivery system which demonstrated sustained release of the drug through the patches. The formulation F1 containing hydrophilic and lipophilic polymers (3:1 ratio) showed the maximum release and permeation of drug for a longer time period up to 12 hours which made it suitable for the development of sustained release patches of piroxicam.

Keyword: Dysmenorrhea piroxicam transdermal patch NSAID sustained.

Citation:

Mahajan NM, Zode GH, Mahapatra DK, Thakre S, Dumore N, Gangane PS. Formulation development and evaluation of transdermal patch of piroxicam for treating dysmenorrhoea. J Appl Pharm Sci, 2018; 8(11): 035–041.

Copyright: © The Author(s). This is an open-access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

HTML Full Text

Reference

Arun R. Formulation evaluation and in vitro permeation studies of transdermal nifedipine from matrix types patches. Int J Pharm Pharm Sci, 2014; 6(1):185–88.
Beale JM, Block JH. Wilson and Gisvold's textbook of organic medicinal and pharmaceutical chemistry. Lippincott Williams & Wilkins, Philadelphia, PA, 2011.
Brunton L, Parker K, Blumenthal D, Buxton I. Goodman & Gilman's manual of pharmacology and therapeutics. The McGraw-Hill, New York, NY, 2008.
Colledge NR, Walker BR, Ralston SH. Davidson's principles and practice of medicine. Elsevier, New York, NY, 2010.
Craig CR, Stitzel RE. Modern pharmacology with clinical applications. Lippincott Williams & Wilkins, Philadelphia, PA, 2004.
Dahodwala ST, Sheikh A. Formulation and evaluation of transdermal film of promethazine hydrochloride. J Adv Pharm Edu Res, 2013; 3(4):559–65.
Dangre PV, Godbole MD, Ingale PV, Mahapatra DK. Improved dissolution and bioavailability of eprosartan mesylate formulated as solid dispersions using conventional methods. Indian J Pharm Edu Res, 2016; 50(3):S209–17.https://doi.org/10.5530/ijper.50.3.31
Darwhekar G, Jain DK, Patidar VK. Formulation and evaluation of of clopidogrel bisulfate. Asian J Pharm Life Sci, 2011; 1(3):269–78.
Dey SK, De PK, Sen T, Shankar V, Banerjee U. Formulation and in vitro evaluation of transdermal matrix patches of diclofenac sodium. J Pharm Res, 2011; 4(10):3593–6.
Godbole MD, Mahapatra DK, Khode PD. Fabrication and characterization of edible jelly formulation of stevioside: a nutraceutical or OTC aid for the diabetic patients. Inventi Nutraceut, 2017; 2017(2):1–9.
Gudalwar BR, Borkar VK, Sonkamble MK, Khalkar SG, Jadhav JK. Development of bilayered transdermal patches of ondansetron hydrochloride: physicochemical and ex vivo characterization. Int J Pharma World Res, 2012; 3(2):1–22.
Kumar SS, Behury B, Sachinkumar P. Formulation and evaluation of transdermal patch of Stavudine. Dhaka Univ J Pharm Sci, 2013; 12(1):63–9.https://doi.org/10.3329/dujps.v12i1.16302
Kumar SR, Jain A, Nayak S. Development and evaluation of transdermal patches of colchicine. Der Pharm Lett, 2012; 4(1):330–43.
Kumar V, Cotran RS, Robbins SL. Basic pathology. W B Saunders Company, Philadelphia, PA, 1992.
Lemke TL, Williams DA. Foye's principles of medicinal chemistry. Lippincott Williams & Wilkins, Philadelphia, PA, 2012.
Mahajan NM, Pardeshi A, Mahapatra DK, Darode A, Dumore NG. Hypromellose and Carbomer induce bioadhesion of Acyclovir tablet to vaginal mucosa. Indo Am J Pharm Res, 2017a; 7(12):1108–18.
Mahajan NM, Wadhwane P, Mahapatra DK. Rational designing of sustained release matrix formulation of etodolac employing hypromellose, carbomer, eudragit and povidone. Int J Pharm Pharm Sci, 2017b; 9(12):92–7.https://doi.org/10.22159/ijpps.2017v9i12.19702
Mahapatra DK, Bharti SK. Handbook of research on medicinal chemistry: innovations and methodologies. 1st edition, Apple Academic Press, New Jersey, 2017.https://doi.org/10.1201/9781315207414
Mohamad M, Tabassum N, Ali J, Jan R. Preparation and evaluation of transdermal patch of aceclofenac. J Pharm Res, 2012; 5(1):331–2.
Nanda S, Saroha K, Yadav B, Sharma B. Formulation and characterization of transdermal patch of amlodipine besylate. Int J Pharm Chem Sci, 2012; 1(3):953–69.
Patel KN, Patel HK, Patel VA. Formulation and characterization of drug in adhesive transdermal patches of diclofenac acid. Int J Pharm Pharm Sci, 2012; 4(1):296–9.
Patel MP, Gupta MM. Formulation development and evaluation of transdermal patch of anti-diabetic drug pioglitazone. Pharm Innov, 2013; 2:80–8.
Patil MD, Mahapatra DK, Dangre PV. Formulation and in-vitro evaluation of once-daily sustained release matrix tablet of nifedipine using rate retardant polymers. Inventi Impact Pharm Tech, 2016; 4:190–6.
Singh A, Bali A. Formulation and characterization of transdermal patches for controlled delivery of duloxetine hydrochloride. J Anal Sci Technol, 2016; 7(1):25.https://doi.org/10.1186/s40543-016-0105-6
Umaredkar AA, Dangre PV, Mahapatra DK, Dhabarde DM. Fabrication of chitosan-alginate polyelectrolyte complexed hydrogel for controlled release of cilnidipine: a statistical design approach. Mater Technol, 2018:1–1.https://doi.org/10.1080/10667857.2018.1456617

Article Metrics

761 Views 241 Downloads 1002 Total

Year

Month

Related Search

By author names

Mahajan N M [PubMed] [Google Scholar ]

Zode G H [PubMed] [Google Scholar ]

Mahapatra D K [PubMed] [Google Scholar ]

Thakre S [PubMed] [Google Scholar ]

Dumore N [PubMed] [Google Scholar ]

Gangane P S [PubMed] [Google Scholar ]

By article title